Despite the association with a high PD-L1 expression in a small cohort of resected NSCLC specimens [31], the presence of activating EGFR mutations is associated with low expression of PD-L1 on tumor cells, as well as a poor outcome to ICIs [16,32,33,34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.